Efficacy of montelukast in patients aged 2 to 5 years with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 377s Year: 2004
Economic evaluation of eformoterol compared with salmeterol in children aged 6-17 years with symptomatic asthma in the UK: cost-effectiveness results of the FACT study Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001
Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks Source: Eur Respir J 2002; 20: Suppl. 38, 406s Year: 2002
Low dose inhaled fluticasone propionate compared with montelukast in children 6-12 years old Source: Eur Respir J 2003; 22: Suppl. 45, 535s Year: 2003
Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Formoterol in acute asthma in children 6-14 years old Source: Eur Respir J 2003; 22: Suppl. 45, 133s Year: 2003
Does fluticasone or montelukast reduce the risk of recurency of wheezing bronchitis comparing to no intervention in children under the age of 3 Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Comparative study of 8-weeks treatment of asthma exacerbations in adults with high doses of budesonide versus fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001
Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Follow-up results 10 years after early intervention with budesonide or terbutaline in mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
Montelukast compared with fluticasone proprionate in children with persistent asthma Source: ISSN=ISSN 1810-6838, ISBN=, page=267 Year: 2006
The effect of fluticasone vs fluticasone plus salmeterol on allergen-induced bronchial inflammation in asthmatic patients. A long-term RCT Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Adding montelukast versus doubling the budesonide dose in persistent asthma: a subgroup analysis of the COMPACT study Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Efficacy of reslizumab in adults with severe eosinophilic asthma with =3 exacerbations in the previous year: analyses at weeks 16 and 52 of two placebo-controlled phase 3 trials Source: International Congress 2017 – Asthma epidemiology among children and adults: from biomarkers to ACOS Year: 2017
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013